Page last updated: 2024-10-28

ifosfamide and Anemia

ifosfamide has been researched along with Anemia in 27 studies

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma."9.14Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."9.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."9.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma."7.83Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."7.81[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)."7.77Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011)
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma."5.14Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."5.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."5.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma."3.83Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."3.81[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded."3.78Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ( Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL, 2012)
"In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)."3.77Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011)
"Ifosfamide was administered at a fixed dose of 1."2.71Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004)
"Grade 3 thrombocytopenia was observed in five cases (36%)."2.71Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005)
"Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients."2.71Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005)
"Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna."2.70Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001)
"Fever is a very rare presentation of splenic angiosarcoma."2.52Primary splenic angiosarcoma with fever and anemia: a case report and literature review. ( Chang, W; Chen, J; Deng, R; Tao, K; Wu, X; Zhang, P, 2015)
"Ifosfamide is an alkylating agent which has poorly understood toxic side effects such as encephalopathy."1.30Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. ( Baerlocher, GM; Beer, JH; Cerny, T; Meiselman, HJ; Owen, GR; Reinhart, WH, 1999)
"Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo."1.27Ifosfamide in advanced pancreatic cancer. A 5-year experience. ( Gad-el-Mawla, N, 1986)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19902 (7.41)18.7374
1990's7 (25.93)18.2507
2000's7 (25.93)29.6817
2010's10 (37.04)24.3611
2020's1 (3.70)2.80

Authors

AuthorsStudies
Sang, W1
Shi, M1
Yang, J2
Cao, J1
Xu, L1
Yan, D1
Yao, M1
Liu, H1
Li, W1
Zhang, B1
Sun, K1
Song, X1
Sun, C1
Jiao, J1
Qin, Y2
Sang, T1
Ma, Y1
Wu, M1
Gao, X1
Cheng, H1
Yan, Z1
Li, D1
Sun, H1
Zhu, F1
Wang, Y1
Zeng, L1
Li, Z1
Zheng, J1
Xu, K1
Blay, JY1
Leahy, MG1
Nguyen, BB1
Patel, SR1
Hohenberger, P1
Santoro, A1
Staddon, AP1
Penel, N1
Piperno-Neumann, S1
Hendifar, A1
Lardelli, P1
Nieto, A1
Alfaro, V1
Chawla, SP1
Kakutani, S1
Fukuhara, H1
Taguchi, S1
Nagata, M1
Niimi, A1
Hattori, M1
Miyazaki, H1
Fujimura, T1
Nakagawa, T1
Kume, H2
Igawa, Y1
Homma, Y1
Yin, ZM1
Yu, AJ1
Wu, MJ1
Fang, J1
Liu, LF1
Zhu, JQ1
Yu, H1
Hu, S1
He, X1
Dong, M1
Jia, B1
Zhou, S1
Yang, S1
Zhang, C1
Liu, P1
Gui, L1
Deng, R1
Chang, W1
Wu, X1
Chen, J1
Tao, K1
Zhang, P1
Lee, AC1
Abu-Khalaf, MM1
Raza, MA1
Hatzis, C1
Wang, H1
Lin, K1
Higgins, S1
Ratner, E1
Silasi, DA1
Azodi, M1
Rutherford, TJ1
Santin, AD1
Schwartz, PE1
Coriat, R1
Mir, O1
Camps, S1
Ropert, S1
Billemont, B1
Leconte, M1
Larousserie, F1
Anract, P1
Alexandre, J1
Goldwasser, F1
Motomura, K1
Natsume, A1
Fujii, M1
Ito, M1
Momota, H1
Wakabayashi, T1
Gupta, AA1
Anderson, JR1
Pappo, AS1
Spunt, SL1
Dasgupta, R1
Indelicato, DJ1
Hawkins, DS1
Kerbusch, T1
Groenewegen, G1
Mathôt, RA1
Herben, VM1
ten Bokkel Huinink, WW1
Swart, M1
Ambaum, B1
Rosing, H1
Jansen, S1
Voest, EE1
Beijnen, JH1
Schellens, JH1
Worden, FP1
Taylor, JM1
Biermann, JS1
Sondak, VK1
Leu, KM1
Chugh, R1
McGinn, CJ1
Zalupski, MM1
Baker, LH1
Takahashi, S1
Suzuki, M1
Matsumoto, S1
Okamoto, N1
Nishimatsu, H1
Tomita, K1
Kitamura, T1
Lorusso, V1
Gebbia, V1
Spada, M1
Guida, M1
Cassano, G1
Brunetti, C1
Germano, D1
Nettis, G1
Izzi, G1
Galetta, D1
Giampaglia, M1
Silvestris, N1
Colucci, G1
Su, Y1
Hartlapp, JH1
Jaeger, N1
Fischer, P1
Weissbach, L1
de Campos, E1
Radford, J1
Steward, W1
Milroy, R1
Dougal, M1
Swindell, R1
Testa, N1
Thatcher, N1
Rao, SP1
Miller, ST1
Cohen, BJ1
Lokich, J1
Anderson, N1
Moore, C1
Bern, M1
Coco, F1
Dow, E1
Hempling, RE1
Eltabbakh, GH1
Piver, MS1
Recio, FO1
O'Neill, CP1
Zarogoulidis, K1
Papagiannis, A1
Ziogas, E1
Fahantidou, E1
Dermitzakis, G1
Gioulekas, D1
Vamvalis, C1
De Pas, T1
De Braud, F1
Orlando, L1
Nolè, F1
Munzone, E1
Zampino, MG1
Fazio, N1
Aapro, MS1
Goldhirsch, A1
Reinhart, WH1
Baerlocher, GM1
Cerny, T1
Owen, GR1
Meiselman, HJ1
Beer, JH1
Thurnher, D1
Kornfehl, J1
Burian, M1
Gedlicka, C1
Selzer, E1
Quint, C1
Neuchrist, C1
Kornek, GV1
Pectasides, D1
Aravantinos, G1
Kalofonos, H1
Kiamouris, C1
Bafaloukos, D1
Xiros, N1
Nicolaides, C1
Visvikis, A1
Dimopoulos, MA1
Gad-el-Mawla, N1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178]Phase 1/Phase 220 participants (Anticipated)Interventional2017-03-01Recruiting
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120]Phase 3121 participants (Actual)Interventional2008-11-30Completed
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841]Phase 3250 participants (Anticipated)Interventional2014-07-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

6-month Progression - Free Survival

Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Trabectedin66.7
Doxorubicin Plus Ifosfamide78.3

Duration of Response (DOR)

The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months

Interventiondays (Median)
TrabectedinNA
Doxorubicin Plus IfosfamideNA

Overall Survival

Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)

Interventionmonths (Median)
Trabectedin46.6
Doxorubicin Plus Ifosfamide33.5

Percentage of Participants With Objective Response

Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months

Interventionpercentage of participants (Number)
Trabectedin5.9
Doxorubicin Plus Ifosfamide27.0

Progression - Free Survival (PFS)

The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months

Interventionmonths (Median)
Trabectedin19.6
Doxorubicin Plus Ifosfamide8.3

Reviews

1 review available for ifosfamide and Anemia

ArticleYear
Primary splenic angiosarcoma with fever and anemia: a case report and literature review.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:11

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Chemotherapy, Adj

2015

Trials

14 trials available for ifosfamide and Anemia

ArticleYear
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Cancer medicine, 2020, Volume: 9, Issue:16

    Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R

2020
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:6

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm

2014
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S

2010
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
    British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D

2004
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant

2005
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo

2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Oncology reports, 2005, Volume: 14, Issue:6

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-

2005
[Side-effects of polychemotherapy in metastatic testicular neoplasms (author's transl)].
    Klinische Wochenschrift, 1982, Mar-01, Volume: 60, Issue:5

    Topics: Adult; Alopecia; Anemia; Bleomycin; Ceruletide; Cisplatin; Constipation; Cyclophosphamide; Drug Ther

1982
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small C

1995
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    The Journal of infusional chemotherapy, 1996,Winter, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che

1996
The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma.
    American journal of clinical oncology, 1997, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Combined C

1997
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib

1998
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He

2001

Other Studies

12 other studies available for ifosfamide and Anemia

ArticleYear
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:3

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce

2015
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
    European journal of gynaecological oncology, 2015, Volume: 36, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendo

2015
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:8

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid

2015
A Child with Rapid-onset Respiratory Distress after Chemotherapy, Lung Irriadiation, General Anaesthesia, and Blood Transfusion.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:11

    Topics: Abdominal Neoplasms; Acute Lung Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chil

2015
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
    European journal of gynaecological oncology, 2016, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap

2016
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:11

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Sy

2011
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Cancer, 2012, Feb-15, Volume: 118, Issue:4

    Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc

2012
[Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubi

2006
B19 parvovirus infection in children with malignant solid tumors receiving chemotherapy.
    Medical and pediatric oncology, 1994, Volume: 22, Issue:4

    Topics: Acute Disease; Adolescent; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chil

1994
Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:14

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Erythrop

1997
Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood.
    European journal of haematology, 1999, Volume: 62, Issue:4

    Topics: Adult; Anemia; Antineoplastic Agents, Alkylating; Cell Aggregation; Erythrocyte Deformability; Eryth

1999
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adult; Alopecia; Anemia; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middl

1986